Wegovy Weight-Loss Pills Approved for Use in the UK

The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has officially approved a new pill version of the weight-loss drug Wegovy. This development marks the first time that a tablet form of this specific medication has been cleared for use in the country. The decision makes the UK the third nation to authorize the pills, following the United States and the United Arab Emirates.

Wegovy contains a substance called semaglutide. This works by mimicking a natural hormone in the body known as GLP-1, which helps to suppress appetite and slows down digestion. By doing so, it helps people feel fuller for longer periods. According to the BBC, the manufacturer, Novo Nordisk, stated that the once-a-day tablet could be more convenient for many patients than the current weekly injections. Furthermore, unlike the injectable version, the pills do not need to be kept in a refrigerator.

While the approval is a significant step, the drug will not be available through the National Health Service (NHS) immediately. The National Institute for Health and Care Excellence (Nice) must first assess the drug to decide if it should be recommended for general use. According to the BBC, while Nice has not yet been formally approached by the manufacturer, the two parties are currently in active dialogue. For now, patients who wish to use the drug will need to obtain a private prescription from pharmacies.

Clinical trials have shown that patients on the highest dose of the medication lost between 14% and 17% of their body weight after 64 weeks. The MHRA has set clear guidelines for how the drug should be used. Patients will start on a 1.5 mg dose, which will gradually increase to 4 mg, 9 mg, and finally 25 mg over several months. Those who are already using the 2.4 mg weekly injection may be able to switch directly to the 25 mg daily tablet, provided their doctor agrees it is suitable.

Despite the excitement surrounding the new form of the drug, medical experts are urging caution. Prof. Victoria Tzortziou Brown, president of the Royal College of GPs, noted that while the tablet form is easier to take than an injection, it should not be viewed as a "magic solution" for weight loss. She emphasized that the medication comes with potential side effects and is not appropriate for everyone. Common issues reported by users include nausea, vomiting, constipation, and diarrhea. The MHRA advises that anyone experiencing these side effects should report them to their doctor or through the official yellow card scheme.

Furthermore, health professionals stress that the medication is intended for specific groups, such as adults who are obese or those who are overweight and have at least one weight-related health condition. It is not meant for short-term or cosmetic weight loss. Experts strongly advise against using these drugs as a quick fix to get ready for specific events. Instead, the medication should be part of a broader approach to health, which includes a balanced diet, regular physical activity, and behavioral support.

Olivier Picard, the chair of the National Pharmacy Association, called the approval "significant" and noted that it could help many patients who are unable or unwilling to use the injectable version. He added that pharmacies are currently waiting for further guidance on when the treatment will be available to the public. While the exact cost in the UK is not yet known, patients hope that the tablet form might eventually reduce the cost of treatment compared to the current private prices for injections, which can range from £90 to £300 per month.

As the UK joins other nations in offering this new treatment option, the focus remains on ensuring it is used safely. The long-term success of the medication depends on the patient's commitment to lifestyle changes. As noted by the BBC, there is always a risk that weight may return after a patient stops taking the medication. Therefore, medical professionals continue to emphasize that the drug is a tool to support, not replace, healthy habits.